Featured
Following the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommendation, Sera Prognostics will stop study enrollment to focus on analyzing and reporting the data. Either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis, and enrollment has been halted for efficacy.
Epic Sciences’ 56-gene ctDNA panel, a key component of the comprehensive DefineMBC blood biopsy for metastatic breast cancer, is now covered under a Medicare program for molecular diagnostic tests.
Funding will accelerate commercialization of Gemelli’s trio-smart® and ibs-smart® precision diagnostic tests for IBS and SIBO, and its strategies for gastrointestinal discoveries related to the microbiome
Funding will accelerate commercial launch of DefineMBC™ and expand Epic Sciences' liquid biopsy solutions for key global oncology trials
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.
The agreement with MultiPlan for participation in its networks will help expand access to the PreTRM® Test to allow more timely intervention to the members accessing MultiPlan’s services through its more than 700 healthcare payers and the 1.2 million participating healthcare providers.
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).
Results confirmed that a U.S. validated proteomics predictor could be applied in low- and middle- income countries to help address global preterm birth challenges
Sera Prognostics appoints Zhenya Lindgardt and Sandra A. J. Lawrence to its Board of Directors
Dr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company’s efforts to help address the healthcare disparities that disproportionately affect underserved communities.
Publication illustrates the power of stratifying PreTRM® testing risk at or above a threshold of twice the average population risk of spontaneous preterm birth (sPTB).
Partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, to include distribution of a children’s book with essential prenatal healthcare information and support in the form of pregnancy/NICU “care boxes”
Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs. Positive impact on preterm births, neonatal intensive care admissions, overall hospital length of stay and a net $54 million reduction in total costs in the analyzed population.
Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
Sera Prognostics releases health and economic benefits analysis of its PreTRM test, and announces commercial partnership with Anthem, Inc.
Sera Prognostics said on Thursday that it has closed a $100 million Series E financing round.
The round was led by existing investors Anthem and Blue Ox Healthcare Partners, with participation from Vivo Capital, aMoon Fund, and Parian Global. In conjunction with the round, Anthem Chief Analytics Officer Marcus Wilson, Anthem VP of Emerging Markets and Partnerships Elizabeth Canis, and Vivo Capital Managing Director Joe Siletto have joined Sera's board.
The pharmaceutical industry delivered a Covid-19 vaccine with unprecedented speed. What comes next in Covid treatments and other medical breakthroughs? Where are investment opportunities? A Barron's Roundtable on healthcare investing with Mikael Dolsten, chief scientist at Pfizer; Louise A. Chen, senior analyst at Cantor Fitzgerald; and Charles D. Kennedy, M.D., CEO of Blue Ox Healthcare Partners.
Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, together with leading health benefits company Anthem, Inc. and its HealthCore, Inc. subsidiary, an evidence generation company, have launched and started to enroll patients in a study to determine whether a test, along with clinical interventions, can lead to improved health for newborns and mothers.
Sera Prognostics’ partnership with Anthem shows Blue Ox playbook in action. Joining forces on a clinical study to improve neonatal outcomes, the partnership illustrates Blue Ox’s strategy of backing innovations that both lower healthcare costs and improve patient outcomes.
Charles sat down with Dechert’s Robert Darwin to discuss how PE investments in life sciences and healthcare fared in 2020, and what’s in store for those sectors this year and in years to come.
Dr. Charles Kennedy, CEO of Blue Ox Healthcare Partners, discusses updates in treatments and vaccines for Covid-19.
Charles discusses the lessons learned from the COVID pandemic as well as the impact it will have on the healthcare industry and the investment environment going forward.
Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, to provide consulting services to Obalon, including helping Obalon to develop and implement an effective coverage and reimbursement-based go-to-market strategy.
Dr. Charles Kennedy, chief executive officer and managing partner at Blue Ox Healthcare Partners, discusses the impact of Covid-19 on deals in the health care space, and what investment opportunities the pandemic has presented in the industry. He speaks on "Bloomberg Markets."
Sera Prognostics, Inc. today announced the appointment of Thomas J. Garite, M.D. as Vice President of Clinical Sciences. Dr. Garite will work closely with Sera to advance clinical development programs that support the company’s growth from development into a commercial-stage company.